Bayer's Faith In Pharma Pipeline Paying Off
Positive News For Nubeqa and Kerendia
The German major has presented the latest developments in the ongoing transformation of its pharmaceuticals business, starting with the prostate cancer therapy Nubeqa which Bayer believes will be a €3bn drug, way up on its earlier estimate of €1bn.
You may also be interested in...
Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
In this week's podcast edition of Five Must-Know Things: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and Scrip Asks experts about prospects for pharma science and technology in 2022.